N/A N=41 Neurogenic Inflammation in Diabetes
Diabetes Mellitus · Polyneuropathies · Arthropathy, Neurogenic
Primary: Induration Size as a Response to Intracutaneous Candida Albicans. — 4; 6; 5; 4 millimeters — p=0.84
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=63 Chronic Neuropathy Following Chemotherapy
Peripheral Nervous System Diseases · Chronic Pain
Primary: Chemotherapy-induced Peripheral Neuropathy — 21 participants
N/A N=140 Effect of Exercise and Surgical Weight Loss on Polyneuropathy
Polyneuropathies · Obesity · Bariatric Surgery Candidate
Primary: Intraepidermal Nerve Fiber Density (IENFD) at the Proximal Thigh — 11.9; 12.7; 9.8; 11 fibers/mm — p=0.15
N/A N=10 Effect Of Mesenchymal Stem Cells Transfusion on the Diabetic Peripheral Neuropathy Patients .
Diabetic Peripheral Neuropathy
Primary: Measurement of b-FGF, v-EGF MEASURED BY ELISA — 30.2; 55.4; 30.3; 428.7 pg/ml — p=0.005
Phase 3 N=256 Efficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain.
Neuropathic Pain
Primary: Neuropathic Pain in Subjects With Peripheral Neuropathic Pain Conditions During the Double-blind Phase — 2.84; 3.62 score on scale — p=0.0018
Phase 3 N=319 A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients
Cancer
Primary: Neurotoxicity Assessment at Baseline — 8.5; 7.3; 5.23; 4.58 units on a scale
N/A N=34 Lidocaine for Diabetic Peripheral Neuropathy
Diabetes · Peripheral Neuropathy · Pain
Primary: Change in Spontaneous Pain at 60-120 Minutes After Lidocaine Infusion Initiated (Assessed on 0-10 NRS) — 33; 51 percentage of pain change from baseline — p=0.03
Phase 3 N=75 Neuropathic Pain Management
Diabetic Neuropathies · Polyneuropathies
Primary: Mean Neuropathic Pain Score at Visit 3 (Week 1) — 51.00; 50.70 Units on a Scale
N/A N=44 Reversing Diabetic Peripheral Neuropathy Through Exercise
Peripheral Neuropathy · Diabetes
Primary: Body Mass Index (BMI) — 30.7 kg/m^2
Phase 3 N=61 Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy
Type 1 Diabetes · Peripheral Neuropathy
Primary: Skin Biopsy - Intraepidermal Nerve Fiber Density (IENFD) - Distal Thigh — 12; 14 Percentage change in IENFD
N/A N=72 Improving Neuropathy and Mobility in People With Early Diabetes
Diabetes · Physical Activity
Primary: Six Minute Walk (6MW) Test — 156.644156; 61.257846 feet
Phase 2 N=40 Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-Induced Peripheral Neuropathy · Malignant Solid Neoplasm
Primary: Change in Chemotherapy-induced Peripheral Neuropathy (CIPN) From Baseline — 147.95; 135.82; 167.96; 148.45 percentage of change in CIPN
N/A N=44 Corneal Nerves Function and Structure
Diabetic Peripheral Neuropathy
Primary: Cornea Sensitivity — 0.177; 0.293 time ratio of eyelids closed vs. open — p=<0.001
N/A N=101 Effect of Exercise on Gait and Balance in Peripheral Neuropathy
Diabetic Neuropathies · Peripheral Nerve Diseases · Peripheral Nervous System Diseases
Primary: Gait and Balance Measures — 51.3; 51.2; 52.3 units on a scale
Phase 4 N=121 Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP
Diabetic Peripheral Neuropathic Pain (DPN) · Postherpetic Neuralgia (PHN) · HIV-related Neuropathic Pain (HIV)
Primary: Change From Baseline to End of Treatment (EOT) in Weekly Mean Pain Score on the Daily Pain Rating Scale (DPRS) — -3.8 scores on scale — p=< 0.0001
Phase 2 N=273 A Study for Treatment of Pain in Patients With Diabetic Neuropathy.
Diabetic Neuropathy, Painful
Primary: Change From Baseline in Weekly Mean 24-hour Average Pain Severity (APS) Score at 5 Weeks — -2.08; -2.22; -2.45; -2.42 units on a scale
Phase 2 N=452 Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
Diabetic Peripheral Neuropathy
Primary: Mean Change From Baseline to Week 5 in Average Daily Pain Score (ADPS) Following Treatment With DS-5565 Compared to Pregabalin and Placebo — -1.86; -1.79; -2.04; -2.32…
Phase 1 N=104 Neuropathic Pain Syndrome Patient Study (MK-0000-072)
Neuralgia, Postherpetic · Diabetic Neuropathy · Painful Small-Fiber Neuropathy
Primary: Daily Evening Patient Reported Pain Intensity Scores — 0.14; 1.57 Units on a Scale — p=0.003
Phase 2 N=301 Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
Diabetic Peripheral Neuropathy
Primary: Numeric Rating Scale (NRS) Average Pain Intensity — -1.50; -1.61; -1.15; -1.23 score on a scale
Phase 2 N=132 Topiramate for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN)
Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome
Primary: Intraepidermal Nerve Fiber Density (IENFD) — -0.6064; -0.396 fibers/mm/year (52 weeks)
Phase 4 N=402 Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations
Cryptogenic Sensory Polyneuropathy
Primary: Co-Primary Measures: Percent of Patients With at Least a 50% Decrease in Likert Pain Scale From Baseline to Week 12 Follow Up and Percent of Patients That Quit — 34; 29…
N/A N=46 Evaluation of Exenatide in Patients With Diabetic Neuropathy
Type 2 Diabetes Mellitus · Diabetic Peripheral Neuropathy
Primary: Confirmed Clinical Neuropathy (CCN) — 14; 18 participants
Phase 2 N=12 Gene Therapy for Painful Diabetic Neuropathy
Painful Diabetic Peripheral Neuropathy
Primary: Treatment-emergent Adverse Events for Participants Who Received Engensis 4 mg, 8 mg, or 16 mg — 3; 2; 2; 1 Participants
N/A N=14 Electrical Stimulation in Diabetic Peripheral Neuropathy
NMES · Control
Primary: Nerve Conduction Speed (Common Peroneal Nerve) — 33.93; 44.1; 41.63; 44.13 m/sec
N/A N=45 Exercise-facilitated Neurorehabilitation in Diabetic Neuropathy
Diabetic Neuropathy
Primary: Sural Nerve Amplitude — 1.22; 2.37; 0.88; 0.86 uV — p=0.49
Phase 4 N=40 A Randomized Double-Blind Study Testing the Effects of Pregabalin on Diabetic Neuropathy
Diabetic Neuropathy
Primary: Assessing the Change in Resting Blood Pressure Upon Treatment of Pregabalin vs. Placebo in Patients With Diabetes and Peripheral Neuropathy. — -7.63; -8.98; -4.41; -4.93…
N/A N=39 Effect of Cocoa Supplementation Peripheral and Autonomic Diabetic Neuropathy
Diabetic Neuropathies
Primary: Toronto Clinical Scoring System (TCSS) — -2.63; -1.84; 9.31; 6.89 Score on a scale — p=>0.05
Phase 2 N=2 Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Neuropathy
Peripheral Neuropathy
Primary: Identification of the Optimal Dose of ALA Based on Acceptable Adverse Event(AE) Profile — 500 mg
N/A N=161 Symptom Management Efficacy Study to Reduce Distal Neuropathic Pain
Neuropathic Pain · HIV Neuropathy · HIV/AIDS
Primary: Gracely Pain Scale (GPS) — -2.51; -1.96; -2.38; -0.99 GPS pain score on a scale
Phase 3 N=665 Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy
Diabetic Neuropathy, Painful
Primary: Change From Single-Blind Baseline in Mean Pain Score at Week 19 During Double-Blind Phase — 6.8; 6.7; -3.9; -3.5 units on a scale — p=0.1221